---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013534"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:51:39.709086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026

## Summary
- GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.
- Islets from treated mice showed insulin secretion similar to normal-diet mice; improved beta-cell function and maturation.
- Treatment increased mature insulin granules and decreased immature granules in beta cells.
- Approach deemed potentially translatable to humans via endoscopic retrograde cholangiopancreatography (ERCP).
- Data to be presented at ASGCT Annual Meeting, May 11-15, 2026 in Boston.

## SEC filing metadata
- accession: 0001437749-26-013534
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926013534/0001437749-26-013534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926013534/gnpx20260424_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013534
- JSON: https://secwatch.observer/filing/0001437749-26-013534.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.